MIRA (Mira Pharmaceuticals) EBIT: $-9.79 Mil (TTM As of Mar. 2026)

What is Mira Pharmaceuticals EBIT?

Mira Pharmaceuticals MIRA -4.57% 13 EBIT is $-9.79 Mil as of Mar. 2026. GuruFocus rates MIRA with a GF Score™ of 13/100. The stock has 1 warning sign investors should review.

Mira Pharmaceuticals's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-1.10 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-9.79 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Mira Pharmaceuticals's annualized ROC % for the quarter that ended in Mar. 2026 was -5,767.32%. Mira Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Mira Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -33.94%.

Mira Pharmaceuticals (NAS:MIRA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Mira Pharmaceuticals's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

	ROC % (Q: Mar. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2025 )	+	Invested Capital (Q: Mar. 2026 ))	/ count )
=	-4.412 * ( 1 - 0% )	/	( (0.036	+	0.117)	/ 2 )
=	-4.412	/	0.076499999999999
=	-5,767.32 %

where

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	11.094	-	0.702	-	( 11.03	-	max(0, 0.702	-	11.058	+	11.03	))
=	0.036

	Invested Capital		(Q: Mar. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	9.464	-	0.034	-	( 9.407	-	max(0, 0.115	-	9.428	+	9.407	))
=	0.117

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Mira Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2026 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2025		Q: Mar. 2026
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-4.412	/	( ( (0 + max(-0.674, 0))	+	(0 + max(-0.093999999999999, 0)) )	/	2 )
=	-4.412	/	( ( 0	+	0 )	/	2 )
=	-4.412	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.028)	-	(0.702	+	0	+	0)
=	-0.674

	Working Capital		(Q: Mar. 2026 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.021000000000001)	-	(0.034	+	0	+	0.081)
=	-0.093999999999999

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Mira Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2026 )
	=	-9.791	/	28.849
	=	-33.94 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mira Pharmaceuticals EBIT Related Terms

Mira Pharmaceuticals EBIT Historical Data

* Premium members only.

The historical data trend for Mira Pharmaceuticals's EBIT can be seen below:

Mira Pharmaceuticals EBIT Chart

Mira Pharmaceuticals Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Dec25

EBIT

-2.15

-7.05

-8.53

-8.02

-10.49

Mira Pharmaceuticals Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBIT	Get a 7-Day Free Trial													-1.81	-1.55	-1.32	-5.83	-1.10

MIRA vs NSRX, SCLX, MDCX: EBIT Comparison

For the Drug Manufacturers - General subindustry, Mira Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mira Pharmaceuticals EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mira Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Mira Pharmaceuticals's EV-to-EBIT falls into.

Save Embed

13GF Score

Mira Pharmaceuticals Inc MIRA

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Mira Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.79 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of $-9.79 Mil mean?

Mira Pharmaceuticals (MIRA) has a EBIT of $-9.79 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Mira Pharmaceuticals.

Is Mira Pharmaceuticals' EBIT too high?

Mira Pharmaceuticals' current EBIT is $-9.79 Mil. Overall, Mira Pharmaceuticals has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.

How does Mira Pharmaceuticals' EBIT compare to NSRX and SCLX?

Mira Pharmaceuticals' EBIT of $-9.79 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Drug Manufacturers company?

A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Mira Pharmaceuticals. Mira Pharmaceuticals's current EBIT is $-9.79 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Mira Pharmaceuticals stock overvalued right now?

Mira Pharmaceuticals (MIRA) has a current EBIT of $-9.79 Mil. The current EBIT is $-9.79 Mil. Mira Pharmaceuticals' overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Mira Pharmaceuticals (MIRA), the current EBIT is $-9.79 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mira Pharmaceuticals Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies NSRX SCLX MDCX LLY JNJ ABBV XSWX:ROP MRK LSE:AZN XSWX:NOVN OCSE:NOVO B AMGN GILD PFE BMY XPAR:SAN LSE:GSK TSE:4519 XTER:BAYN TSE:4578

Address 1200 Brickell Avenue, Suite 1950 No. 1183, Miami, FL, USA, 33133

Website https://www.mirapharmaceuticals.com

Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.

13GF Score

Get the complete analysis for MIRA

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.91

Price

View MIRA Analysis

See EBIT data for all stocks →